Datopotamab deruxtecan (2) – Datroway®

Triple-negative breast cancer, first-line treatment

Characteristics

Start date 01.09.2026
Resolution 18.02.2027 – active procedure
INN Datopotamab deruxtecan
Brand name Datroway®
Pharm. company Daiichi Sankyo Deutschland GmbH
G-BA Procedure ID D-1371
Therapeutic area Oncological diseases
Reason for procedure New therapeutic indication

Associated procedures

Datopotamab deruxtecan (2) Datroway® Daiichi Sankyo Deutschland GmbH Oncological diseases Triple-negative breast cancer, first-line treatment n.d. active procedure
Datopotamab deruxtecan (1) Datroway® Daiichi Sankyo Deutschland GmbH Oncological diseases HR+, HER2- breast cancer, following at least one prior course of treatment 4,140–14,160 100% additional benefit not proven


<< List of all resolutions